Tomáš Vaňásek - Concepedia

Author

Tomáš Vaňásek

Also Known As

Bincy Abraham, Jan Ulbrych, T Vanasek, T Vanásek, T Vańásek, T Vaňásek, T. Vanasek, T. Vaňásek, Tomas Vanasek, Tomas Vaňásek

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Charles University University Hospital Hradec Králové University of California San Diego Medical University of Vienna University of Calgary

About

Tomáš Vaňásek is an author at Charles University specializing in medicine, gastroenterology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.7K
2	Gastroenterology	7	7	1.7K
3	Immunology	4	4	795
4	Hepatology	2	2	49
5	Microbiology	1	1	18

Tomáš Vaňásek

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt, The Lancet GastroenterologyTight Control ManagementClinical GastroenterologyUlcerative ColitisMedicine	2017	883
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease William J. Sandborn, Subrata Ghosh, Julián Panés, Clinical Gastroenterology and Hepatology InflammationChronic Inflammatory DiseasesAnti-inflammatoryCrohn ’Gastrointestinal Pharmacology	2014	295
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial Bruce E. Sands, Peter M. Irving, Timothy Hoops, The Lancet ImmunologyClinical TrialsGastroenterologyMaintenance TherapyBiological Therapy	2022	277
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial Séverine Vermeire, William J. Sandborn, Silvio Danese, The Lancet InflammationAutoimmune DiseaseMucosal ImmunologyImmunologyGastroenterology	2017	197
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease Satish Keshav, Tomáš Vaňásek, Yaron Niv, PLoS ONE	2013	134
Value of Doppler Sonography in Revealing Transjugular Intrahepatic Portosystemic Shunt Malfunction Ján Žižka, Pavel Eliáš, Antonı́n Krajina, American Journal of Roentgenology	2000	82
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis Radan Keil, Martin Wasserbauer, Zdena Zádorová, Scandinavian Journal of Gastroenterology	2016	63
Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial Remo Panaccione, Jean–Frédéric Colombel, Simon Travis, Gut	2019	34
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II Walter Reinisch, William J. Sandborn, Silvio Danese, Journal of Crohn s and Colitis	2021	34
Influence of the Secondary Deployment of Expanded Polytetrafluoroethylene–covered Stent Grafts on Maintenance of Transjugular Intrahepatic Portosystemic Shunt Patency Václav Jirkovský, Tomáš Fejfar, Václav Šafka, Journal of Vascular and Interventional Radiology HepatologySecondary DeploymentVascular SurgeryLumen-apposing Metal StentSurgery	2010	31

Page 1